Novan (NOVN) Stock Rating Reaffirmed by HC Wainwright

Share on StockTwits

HC Wainwright reissued their buy rating on shares of Novan (NASDAQ:NOVN) in a research note published on Tuesday. They currently have a $8.00 price target on the stock.

“We eagerly anticipate, any day now, data from the Phase 2 dose-ranging study of SB206—topical nitric oxide (NO) gel—for molluscum contagiosum. We see molluscum as a large, underserved pediatric dermatology opportunity, with no FDA approved Rx treatments, and it is currently the key contributor to our Novan valuation. If Phase 2 is positive, with SB206 demonstrating meaningful molluscum lesion clearance rates at 12-weeks and good tolerability, it should be a transformational catalyst for Novan. Note that the only molluscum comparable, Verrica Pharmaceuticals (VRCA; not rated), which has positive open-label molluscum Phase 2 data and Phase 3 expected in 1Q19, has a $350M market cap—dramatically higher than Novan’s current $68M market cap.”,” HC Wainwright’s analyst wrote.

NOVN has been the subject of a number of other research reports. Zacks Investment Research raised shares of Novan from a hold rating to a buy rating and set a $3.00 price objective for the company in a report on Saturday, August 25th. Piper Jaffray Companies reissued a buy rating and set a $6.00 target price on shares of Novan in a research note on Friday, July 20th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Novan currently has a consensus rating of Buy and an average price target of $7.75.

NOVN traded down $0.05 on Tuesday, reaching $2.62. The stock had a trading volume of 15,529 shares, compared to its average volume of 25,226. Novan has a 12-month low of $2.27 and a 12-month high of $6.23. The stock has a market capitalization of $69.31 million, a price-to-earnings ratio of -1.13 and a beta of 1.17.

Novan (NASDAQ:NOVN) last released its quarterly earnings data on Wednesday, August 8th. The company reported ($0.29) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.29). Novan had a negative net margin of 1,090.89% and a negative return on equity of 999.61%. The company had revenue of $0.65 million during the quarter, compared to analysts’ expectations of $0.60 million. On average, analysts predict that Novan will post -1.04 earnings per share for the current year.

In related news, Director Robert Alexander Ingram bought 50,000 shares of the business’s stock in a transaction dated Friday, September 28th. The stock was acquired at an average price of $2.84 per share, with a total value of $142,000.00. Following the completion of the purchase, the director now directly owns 119,777 shares of the company’s stock, valued at $340,166.68. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO G. Kelly Martin bought 10,000 shares of the business’s stock in a transaction dated Wednesday, September 26th. The shares were bought at an average cost of $2.73 per share, with a total value of $27,300.00. Following the purchase, the chief executive officer now directly owns 40,000 shares of the company’s stock, valued at $109,200. The disclosure for this purchase can be found here. Insiders have bought 110,000 shares of company stock valued at $303,800 in the last three months. Corporate insiders own 8.83% of the company’s stock.

An institutional investor recently bought a new position in Novan stock. Prospera Financial Services Inc purchased a new position in shares of Novan Inc (NASDAQ:NOVN) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 76,102 shares of the company’s stock, valued at approximately $224,000. Prospera Financial Services Inc owned about 0.29% of Novan at the end of the most recent quarter. Institutional investors own 11.67% of the company’s stock.

Novan Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Recommended Story: Relative Strength Index

Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with's FREE daily email newsletter.

Leave a Reply